Swedish Biomimetics 3000 Invents Continuous Peptide Manufacturing Process μLOT®

μLOT® is an entirely new approach to manufacturing therapeutic
peptides, which promises to completely replace traditional large-scale
batch manufacturing. The µLOT® technology provides continuous
manufacturing of peptides enabling in-line process analytical
technologies (PAT) throughout the process, providing an unprecedented
level of quality, control and a significant cost reduction.

Peptide-based medicines are widely used across many therapeutic areas
including cancer, diabetes and autoimmune diseases with the market
projected to rise to $46 billion by 2025.

Jens Burkinsky, CTO of SB3000 commented, “We believe that the μLOT® process
will speed up development, reduce cost and enable the synthesis of drugs
currently not economically or technically possible to produce. At
present the process is applicable to 80% of the market. We are
developing the technology to cover the remaining market by including
novel peptide designs such as lipid- and antibody-conjugations.”

Presently all peptides are produced through batch manufacturing which is
not scalable. To increase production during development and later for
commercial scale involves a considerable risk of failure and delay. The μLOT®
process does not require scale-up --“all development work is done at
commercial scale we just run the equipment longer for larger
quantities” says Jens.

The μLOT® platform is a “chemical assembly line” which uses a
ribbon made of polymer mesh with sachet pockets containing a solid-phase
resin. This moves continuously through all the chemical stages of
manufacture. The ribbon is tailored according to the solid-phase resin,
sachet size and spacing of the sachets to optimise the process.
Throughout the process there is close monitoring of every sachet so that
high quality is assured. In contrast, batch manufacturing can never
guarantee the quality of every part of the batch. If there is an issue
the whole batch has to be discarded causing delays, financial loss, and
significant cost for disposal. μLOT® also dramatically reduces
the use of toxic solvents costing billions of dollars a year.

SB 3000 is currently raising a series A round to complete the final leg
of the development program.

**ENDS**

View source version on businesswire.com: https://www.businesswire.com/news/home/20190328005541/en/